Major pharmaceutical companies are heavily investing in R&D for multiple myeloma treatments across Europe.
Steady: 0 in the last 7 days
Updated oct 22
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Major pharmaceutical companies are heavily investing in R&D for multiple myeloma treatments across Europe.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Pfizer, J&J, BMS, Sanofi, and AbbVie are leading innovation in personalized therapies and are key players in the multiple myeloma treatment market.Sub-event
Major pharma players are increasing R&D investment for myeloma treatments across Europe.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
AbbVie (Netherlands)
company in Zwolle, Netherlands
Nothing else this week.
-
Sanofi (Japan)
company in Tokyo, Japan
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireMultiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda The Global Multiple Myeloma Market is pro